PRMT5 and lung carcinoma: The development of clinically relevant inhibitors for specific PRMTs, particularly for PRMT5, has thus progressed at a phenomenal rate with several Phase I/II clinical trials initiated for adult haematological, breast and lung cancer (14, 22).